

Appl. No. : **10/033,244**
Filed : **December 27, 2001**

REMARKS

Applicants respond below to the specific rejections and objections raised by the Examiner in the Office Action of May 5, 2003.

I. Priority

The Examiner has denied priority to PCT/US99/28551 and other provisional applications. Applicants respectfully submit that in a preliminary amendment filed on August 30, 2002, Applicants claimed priority to U.S. Serial No. 09/866,034, of which the present application is a continuation, and to PCT/US99/28634 and Serial No. 60/112,851. A copy of the preliminary amendment is attached herewith for the Examiner's convenient review.

The nucleic acid of SEQ ID NO:2, which is a subject matter of the presently pending claims, was first disclosed as Figure 2 in Serial No. 60/112,851, filed December 16, 1998. In addition, the same nucleic acid was disclosed as Figure 2 and SEQ ID NO:2 in PCT/US99/28634, filed December 1, 1999, and in Serial No. 09/866,034, filed May 25, 2001. Therefore, Applicants claim priority for SEQ ID NO:2 of the present application to at least December 1, 1999. An Application Data Sheet having the correct priority information is also being submitted herewith.

II. Objections and Rejections under 35 U.S.C. § 101

Claims 22-27 stand rejected under 35 U.S.C. § 101 for allegedly lacking specific and substantial asserted utility or a well established utility. The Examiner concedes on page 3, line 4, of the Office Action that the asserted utility in the present application is credible. In rejecting the claims of the present application the Examiner has based his utility rejections on the alleged lack of utility of the underlying proteins to which the antibodies of the present invention bind. Thus, and without acquiescing to the Examiner's reasoning, it appears that once the utility of the protein PRO1800 is established, the utility of the claimed invention would follow. Accordingly, for the reasons set forth below, Applicants respectfully traverse the Examiner's § 101 rejections.

Appl. No. : 10/033,244
Filed : December 27, 2001

Utility – Legal Standard

According to the Utility Examination Guidelines (“Utility Guidelines”), 66 Fed. Reg. 1092 (2001) an invention complies with the utility requirement of 35 U.S.C. § 101, if it has at least one asserted “specific, substantial, and credible utility” or a “well-established utility.”

Under the Utility Guidelines, a utility is “specific” when it is particular to the subject matter claimed. For example, it is generally not enough to state that a nucleic acid is useful as a diagnostic without also identifying the condition that is to be diagnosed.

The requirement of “substantial utility” defines a “real world” use, and derives from the Supreme Court’s holding in *Brenner v. Manson*, 383 U.S. 519, 534 (1966) stating that “The basic *quid pro quo* contemplated by the Constitution and the Congress for granting a patent monopoly is the benefit derived by the public from an invention with substantial utility.” In explaining the “substantial utility” standard, M.P.E.P. 2107.01 cautions, however, that Office personnel must be careful not to interpret the phrase “immediate benefit to the public” or similar formulations used in certain court decisions to mean that products or services based on the claimed invention must be “currently available” to the public in order to satisfy the utility requirement. “Rather, *any reasonable use that an applicant has identified for the invention that can be viewed as providing a public benefit should be accepted as sufficient*, at least with regard to defining a ‘substantial’ utility.” (M.P.E.P. 2107.01, emphasis added.) Indeed, the Guidelines for Examination of Applications for Compliance With the Utility Requirement, set forth in M.P.E.P. 2107 II (B) (1) gives the following instruction to patent examiners: “If the applicant has asserted that the claimed invention is useful for any particular practical purpose . . . and the assertion would be considered credible by a person of ordinary skill in the art, do not impose a rejection based on lack of utility.”

Proper Application of the Legal Standard

Applicants submit that the gene amplification data provided in the present application are sufficient to establish a specific and substantial utility for the PRO1800 polypeptide.

Gene amplification is an essential mechanism for oncogene activation. It is well known that gene amplification occurs in most solid tumors, and generally is associated with poor prognosis. As described in Example 16 of the present application, the inventors isolated genomic DNA from a variety of primary cancers and cancer cell lines that are listed in Table 7 (page 117

Appl. No. : 10/033,244
Filed : December 27, 2001

of the specification). As a negative control, DNA was isolated from the blood of normal healthy individuals (page 115, lines 22-33). Gene amplification was monitored using real-time quantitative TaqMan™ PCR. The gene amplification results are set forth in Table 7. As explained on page 112, lines 17-19, the results of TaqMan™ PCR are reported in Δ Ct units. It is well-known in the art that “Ct” stands for “threshold cycle.” One Ct unit corresponds to one PCR cycle or approximately a 2-fold amplification, relative to control, two units correspond to 4-fold, 3 units to 8-fold, etc. amplification.

It is well-known in the art how Δ Ct values are calculated. The TaqMan™ real-time PCR method, which is used in the methods of the present application, has gained wide recognition for its versatility, sensitivity and accuracy, and is in extensive use for the study of gene amplification. The TaqMan™ 7700 Sequence Detector Software calculates the Ct values for each given experiment. Those of skill in the art know that to obtain Δ Ct, the difference between the Ct values of the test sample and the normal sample is calculated. Furthermore, the specification itself teaches that “The diluted samples were used provided that the Ct value of the normal human DNA subtracted from test DNA was +/- 1 Ct.” Specification at page 116, lines 30-31. Thus, the specification teaches that Δ Ct is obtained when the Ct value of the normal sample is subtracted from the Ct value of the test sample.

As for the significance of the data, the specification states that one Δ Ct unit corresponds to two-fold amplification, two units to four-fold, three units to 8-fold, etc. This fact is also well-known in the art. Thus, the significance of knowing the Δ Ct value is that the extent of gene amplification in a cancer cell is known.

As set forth on page 85, lines 34-37, the disclosed proteins of the invention can be used for tissue typing. Table 7 identifies several tissue types, all obtained from cancerous tumors, in which PRO1800 is amplified. PRO1800 can then be used diagnostically in determining whether a particular tissue type obtained from a patient is cancerous or not. Thus, those of skill in the art recognize the utility of the PRO1800 polypeptide as a diagnostic and therapeutic tool. This utility is specific, since it applies only to those polypeptides where the overexpression of their genes is established, i.e., PRO1800. The utility is also credible, because those of skill in the art recognize that having a diagnostic tool to identify cancer tissues before they have advanced to the point where the disease compromises the life-span of the individual patient, or a therapeutic tool to treat the disease once the patient has been diagnosed with cancer, is quite attractive.

Appl. No. : 10/033,244
Filed : December 27, 2001

Furthermore, the utility is substantial since it can potentially alert medical professionals to the presence of cancer at an early stage when treatment is facile and feasible.

In support of Applicants' assertion of utility, Applicants have submitted herewith a copy of the declaration of Dr. Audrey Goddard with exhibits A-G (the Goddard Declaration), originally submitted in a related and co-owned patent application Serial No. 09/903,925. As Dr. Goddard's *curriculum vitae*, Exhibit A of the Goddard Declaration, shows, she is an expert in the art of identifying and quantifying the amplification of oncogenes in cancers.

In her declaration, Dr. Goddard states that

the quantitative TaqMan PCR technique is technically sensitive enough to detect at least a 2-fold increase in gene copy number relative to control. It is further my considered scientific opinion that an at least 2-fold increase in gene copy number in a tumor tissue sample relative to a normal (i.e., non-tumor) sample is significant and useful in that the detected increase in gene copy number in the tumor sample relative to the normal sample serves as a basis for using relative gene copy number as quantitated by the TaqMan PCR technique as a diagnostic marker for the presence or absence of tumor in a tissue sample of unknown pathology. Accordingly, a gene identified as being amplified at least 2-fold by the quantitative TaqMan PCR assay in a tumor sample relative to a normal sample is useful as a marker for the diagnosis of cancer, for monitoring cancer development and/or for measuring the efficacy of cancer therapy.

The Goddard Declaration, paragraph 7. Therefore, according to Dr. Goddard, a 2-fold increase, i.e., a ΔC_t value of 1, not only is not of questionable significance, but is "significant and useful" in, *inter alia*, detecting cancerous tumors or the diagnosis of cancer. Thus, the Goddard Declaration support Applicants' position that the ΔC_t value of 1 is significant and is outside of the experimental error of this procedure.

Applicants respectfully maintain that the present application as filed contained assertions of utility that go above and beyond the utility requirements set forth by the Office. In view of the above, Applicants respectfully request that the Examiner reconsider and withdraw the rejection.

III. Rejections under 35 U.S.C. § 112, First Paragraph: Scope of Enablement

Claims 22-27 stand rejected under 35 U.S.C. § 112, first paragraph, for allegedly containing a subject matter which is not described in the specification in such a way as to enable one of skill in the art to make or use the invention.

Appl. No. : **10/033,244**
Filed : **December 27, 2001**

Applicants respectfully traverse. In setting forth the rejection, the Examiner correctly cites *In re Wands* and the factors set forth therein to determine the scope of enablement. However, the Examiner's conclusions are not in line with the teachings of *Wands*. For example, given the recent advances in the science of molecular biology, the unpredictability of this art has lessened significantly. As a result, the number of experiments necessary to determine a particular result is now low, and these experiments have become routine in the art. The Examiner concedes that the level of skill in this art is very high, and thus ordinary artisans are expected to be adept in various methodologies in this art and practice them routinely. The breadth of the claims are commensurate with the examples provided in the specification, where the production and use of antibodies that bind to polypeptides that are used diagnostically or therapeutically for certain types of cancer is set forth in detail. Therefore, given the disclosure of the present invention and the level of skill in the present art, Applicants respectfully submit that the present claims are fully enabled.

In view of the above, Applicants respectfully request that the Examiner reconsider and withdraw the rejection.

IV. Rejections under 35 U.S.C. § 102(b)

Claims 22-27 stand rejected under 35 U.S.C. § 102(b) for allegedly being anticipated by Bandman et al (WO 00/04135).

Applicants respectfully traverse. Bandman et al. does not disclose antibodies that bind to the polypeptide of SEQ ID NO:2. The Examiner himself states that "It is *inherent* that antibodies to the Bandman SCRM protein would also interact with SEQ ID NO:2." (Emphasis added.) Applicants respectfully submit that the prophetic disclosure of antibodies in Bandman et al. does not inherently anticipate the claimed subject matter of the present application.

It is well known in the art that antibodies are raised against, and interact with, regions on the surface of polypeptide globules called epitopes. Whether a particular epitope is presented on a surface of a polypeptide globules depends on both the primary structure of the polypeptide molecule and on its tertiary structure. While two polypeptides may show identical local similarities in their amino acid sequence, in one polypeptide the homologous region may be on the surface of the globule while in another polypeptide the homologous region may be buried inside of the globule. The antibodies raised against an epitope comprising the region of

Appl. No. : 10/033,244
Filed : December 27, 2001

homology in the first polypeptide will not necessarily recognize the second polypeptide, since the particular region is not present on the surface.

A single amino acid difference between two proteins may cause a drastic difference in their tertiary structures. The amino acid difference may disrupt an α -helix or a β -turn. Such disruption may cause an epitope that was present on the surface of the first polypeptide molecule not to be present in the second polypeptide. Therefore, it cannot be determined with certainty that an antibody that interacts with the first polypeptide would also interact with a polypeptide containing one or more amino acid differences. This fact is best exemplified by the fact that attempts to find a vaccine for a number of viruses, such as the HIV, has failed primarily because sequence differences in the capsid protein render antibodies raised against the previous version of the virus useless.

As the Examiner's own sequence alignment shows, the polypeptide of Bandman et al., *i.e.*, the SCRM protein has 96% local similarity with the polypeptide of SEQ ID NO:2, *i.e.*, PRO1800. A 4% difference is more than enough to raise the question of whether the tertiary structure of the SCRM protein is identical to the tertiary structure of PRO1800. It is not at all clear *a priori* whether the SCRM protein and PRO1800 present identical epitopes. Thus, at best one may argue that it is *possible*, or perhaps it is *probable*, that any antibody raised against the SCRM protein would bind to PRO1800. Because of the structural differences between the SCRM protein and PRO1800, one cannot say with *certainty* that an antibody raised against one polypeptide would bind to the other. The probability or possibility of the binding of Bandman's antibodies to PRO1800 is further diminished by the fact that the disclosure of Bandman is a prophetic disclosure. Bandman et al. did not in fact raise an antibody against the SCRM protein. They only taught methods by which one of skill in the art arguably could produce an antibody that would interact with the SCRM protein.

As the Federal Circuit has repeatedly held "An inherent limitation is one that is necessarily present; invalidation based on inherency is not established by 'probabilities or possibilities.'" *Elan Pharm., Inc. v. Mayo Found. for Med. Educ. & Research*, 304 F.3d 1221, 1228, 64 USPQ2d 1292, ___ (Fed. Cir. 2002) *quoting Scaltech, Inc. v. Retec/Tetra, LLC.*, 178 F.3d 1378, 1384, 51 USPQ2d 1055, 1059 (Fed. Cir. 1999). However, the Examiner's rejection does not rise above the level of probabilities or possibilities. Applicants respectfully maintain that the Examiner has not shown that the prophetic procedures disclosed in Bandman et al. will

Appl. No. : **10/033,244**
Filed : **December 27, 2001**

necessarily result in antibodies that will always and with certainty bind to PRO1800. Consequently, Applicants respectfully submit that the rejection of the present claims based on anticipation by the inherent disclosure of Bandman et al. is improper. Accordingly, and in view of the above, Applicants respectfully request that the Examiner reconsider and withdraw the rejection.

V. Specification

In reviewing the specification, Applicants encountered some inadvertent errors in numbering the tables and correlating figure numbers to sequence identification numbers. Applicants have herewith submitted amendments to the specification to correct these errors. Applicants submit that these amendments add no new matter and are fully supported by the specification as originally filed.

Appl. No. : 10/033,244
Filed : December 27, 2001

CONCLUSION

Applicants respectfully maintain that claims are patentable and request that they be passed to issue. No fee is believed due in connection with this response. If this is incorrect, the Commissioner is hereby authorized to charge Deposit Account No. 07-0630. Applicants invite the Examiner to call the undersigned if any issues may be resolved through a telephonic conversation.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: _____

Aug. 4, 2003

By: _____

Sam K. Tahmassebi

Sam K. Tahmassebi
Registration No. 45,151
Attorney of Record
Customer No. 30,313
(619) 235-8550

S:\DOCS\SKT\SKT-4033.DOC
072803